Edoxaban is a per oral reversible direct factor Xa inhibitor with the linear pharmacokinetic profile and favourable biological
availability. It is absorbed in the gastrointestinal tract reaching maximum concentration in the plasma 1 to 2
hours after the administration. Its plasmatic half-life is approximately 10 to 14 hours. Significant studies were realised
with edoxaban in three clinical fields. The ENGAGE AF-TIMI 48 study compared edoxaban with warfarin in patients with
non-valvular fibrillation of the atria. The Hokusai-VTE study dealt with the prevention and treatment of venous thromboembolism
(VTE) and pulmonary embolism in comparison to warfarin. The clinical programme STARS was focused on
the prevention of VTE after orthopaedic performances in the field of knee and hip joint in comparison to enoxaparin.
The following text analyses the efficacy and safety of edoxaban in patients with non-vascular FP.